Possibly, the IgM and IgG profiles of serum anti-HLA-HC Abs with or without anti-β2m Abs may reflect the different phases of disease progression and may serve as biomarkers for RA-progression-based therapies. This evidence concerns the gene B2M and rheumatoid arthritis.